← Gordon B. Mills

Papers by Gordon B. Mills

Page 1 · newest first

1. Co-targeting PARP and SHP2 Overcomes Resistance to Apoptosis and Induces Durable Responses in Breast CancerCancer Research · 2026
2. BRD4 is a key regulator of STING expressionCellular Oncology · 2026
3. ACCREDIT: A Quality-Aware Agentic Engine for Cell-resolved Cross-modal Image Registration with Dynamic Iterative Tuning2026
4. Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunitiesMolecular Cancer Research · 2026
5. Abstract PS2-09-24: Aurora Kinase A (AURKA) a new druggable target in ER+ Inflammatory Breast CancerClinical Cancer Research · 2026
6. Abstract PS4-01-10: Characterizing CCR7 Gene Amplification and Protein Expression in Inflammatory and non-inflammatory Breast CancerClinical Cancer Research · 2026
7. Patient-derived xenograft models of Fanconi anemia–associated head and neck cancer identify personalized therapeutic strategiesJournal of Clinical Investigation · 2025
8. CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancerJournal of Clinical Investigation · 2025
9. Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy2025
10. Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response2025
11. Abstract A041: Mutation difference between African American, Asian and White lung adenocarcinoma patientsCancer Epidemiology Biomarkers & Prevention · 2025
12. Nuclear cGAS mediated replication stress and mitotic catastrophe can overcome gemcitabine resistanceCancer Letters · 2025
13. Toward universal immunofluorescence normalization for multiplex tissue imaging with UniFORMCell Reports Methods · 2025
14. The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersBiomarker Research · 2025
15. Automated machine learning profiling with MAP-HR for quantifying homologous recombination foci in patient samplesNAR Cancer · 2025
16. Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancerScience Translational Medicine · 2025
17. Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patientsNature Communications · 2025
18. The role of long non‐coding RNAs in lung cancer metastasis: Molecular mechanisms, pathogenesis and clinical implicationsClinical and Translational Medicine · 2025
19. COEXIST: Coordinated single-cell integration of serial multiplexed tissue imagesPLoS Computational Biology · 2025
20. OmicsTweezer: A distribution-independent cell deconvolution model for multi-omics DataCell Genomics · 2025
21. Utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancernpj Precision Oncology · 2025
22. Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib StudyClinical Cancer Research · 2025
23. Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacyScience Translational Medicine · 2025
24. ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacyCancer Letters · 2025
25. DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysisNature Communications · 2025
26. Automated Machine Learning Profiling with MAP-HR for Quantifying Homologous Recombination Foci in Patient Samples2025
27. Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor–resistant NRAS -mutant melanomaScience Translational Medicine · 2025
28. RAC1-Amplified and RAC1-A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept StudyCancers · 2025
29. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancerNature Cancer · 2025
30. Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersnpj Precision Oncology · 2025
31. Deciphering single-cell heterogeneity and cellular ecosystem dynamics during prostate cancer progression2024
32. UniFORM: Towards Universal ImmunoFluorescence Normalization for Multiplex Tissue Imaging2024
33. UBA1 inhibition sensitizes cancer cells to PARP inhibitorsCell Reports Medicine · 2024
34. Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular AlterationsCancer Discovery · 2024
35. Identifying therapeutic strategies for triple-negative breast cancer via phosphoproteomicsExpert Review of Proteomics · 2024
36. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stressSHILAP Revista de lepidopterología · 2024
37. Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic CancerCancers · 2024
38. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival BenefitMolecular & Cellular Proteomics · 2024
39. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancerFuture Oncology · 2024
40. Single-cell RNA sequencing reveals immunosuppressive pathways associated with metastatic breast cancer2024
41. Abstract C029: Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to targeting RAS/MEK signalingCancer Research · 2024
42. A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies2024
43. Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial2024
44. Strategies for the prevention or reversal of PARP inhibitor resistanceExpert Review of Anticancer Therapy · 2024
45. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsnpj Precision Oncology · 2024
46. Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource2024
47. Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource2024
48. Data from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource2024
49. Supplementary Video S1 from Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas2024
50. Supplementary Video S1 from Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas2024